US2011224213A1PendingUtilityA1
Use of Glutaric Acid Derivatives or the Pharmaceutically Acceptable Salts Thereof as Anti-Arrhythmic Agents
Assignee: NEBOLSIN VLADIMIR EVGENIEVICHPriority: Mar 19, 2008Filed: Mar 18, 2009Published: Sep 15, 2011
Est. expiryMar 19, 2028(~1.6 yrs left)· nominal 20-yr term from priority
Inventors:Vladimir Evgenievich NebolsinDmitry BlinovVladimir Pavlovich BalashovTatyana Alexandrovna KromovaGalina Alexandrovna Zheltukhina
C07D 295/13A61K 31/4172C07D 233/64C07D 209/20C07D 333/20A61K 31/405C07D 207/09A61P 9/06C07D 213/40
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to the use of glutaric acid derivatives of general formula (I), which are disclosed in the invention description, as anti-arrhythmic agents.
Claims
exact text as granted — not AI-modified1 . Use of compounds of general formula (I):
wherein
R 2 =COOH, —COOCH 3 , —COOC 2 H 5 , H,
or a pharmaceutically acceptable salt thereof as an anti-arrhythmic agent.
2 . Use of compounds of general formula (I):
wherein
R 2 =COOH, —COOCH 3 , —COOC 2 H 5 , H,
or a pharmaceutically acceptable salt thereof for the production of a medicament having anti-arrhythmic activity.
3 . A pharmaceutical composition having anti-arrhythmic activity, comprising a compound of general formula (I):
wherein
R 2 =COOH, —COOCH 3 , —COOC 2 H 5 , H,
or a pharmaceutically acceptable salt thereof in an effective amount and a pharmaceutically acceptable carrier.
4 . A medicament having anti-arrhythmic activity, comprising a compound of general formula (I):
wherein
R 2 =COOH, —COOCH 3 , —COOC 2 H 5 , H,
or a pharmaceutically acceptable salt thereof.
5 . A method of treating arrhythmia comprising administering to a mammal an effective amount of a compound of general formula (I):
wherein
R 2 =COOH, —COOCH 3 , —COOC 2 H 5 , H,
or a pharmaceutically acceptable salt thereof.Join the waitlist — get patent alerts
Track US2011224213A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.